Skip to content

CANOPTICS

Transverse Myelitis | Optic Neuritis

Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)are inflammatory diseases of the Central Nervous System (CNS) that are often highly disabling and challenging to treat. CANOPTICS
(the CAnadian Neuromyelitis OPTIca Spectrum Disorder and other atypical demyelinating diseases Cohort Study) will allow us to gain a better understanding of the burden of NMOSD, MOGAD, and other atypical demyelinating diseases in Canada.

null

Participation Requirements

  • Sex:

    Any

  • Eligible Ages:

    19 and up

Participation Criteria

Inclusion Criteria:
Inclusion criteria
1) Diagnosed by a neurologist with an atypical demyelinating disease, including NMOSD, MOGAD, longitudinally extensive transverse myelitis (LETM), recurrent optic neuritis, tumefactive demyelinating diseases, GFAP (glial fibrillary acidic protein) antibody
disease, or a borderline case between NMOSD and multiple sclerosis
2) Must be assessed at the MS clinic at the University of Alberta
3) Understand English
Exclusion Criteria:
For the questionnaire substudy, patients who do not understand English will be excluded

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00108171